Cost-effectiveness and cost-utility of a structured collaborative disease management in the Interdisciplinary Network for Heart Failure (INH) study

被引：0
作者：
Anja Neumann
Sarah Mostardt
Janine Biermann
Götz Gelbrich
Alexander Goehler
Benjamin P. Geisler
Uwe Siebert
Stefan Störk
Georg Ertl
Christiane E. Angerrmann
Jürgen Wasem
机构：
[1] University Duisburg-Essen,Institute for Health Care Management and Research
[2] University of Würzburg,Institute of Clinical Epidemiology and Biometry
[3] UMIT,Department of Public Health and Health Technology Assessment
[4] University of Würzburg,Department of Internal Medicine I and Comprehensive Heart Failure Cente
来源：
Clinical Research in Cardiology | 2015年 / 104卷
关键词：
Heart failure; Economics; Cost-utility; Cost-effectiveness;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：304 / 309
页数：5
相关论文
共 50 条
  • [31] The cost-effectiveness of losartan versus captopril in patients with symptomatic heart failure
    Dasbach, EJ
    Rich, MW
    Segal, R
    Gerth, WC
    Carides, GW
    Cook, JR
    Murray, JF
    Snavely, DB
    Pitt, B
    [J]. CARDIOLOGY, 1999, 91 (03) : 189 - 194
  • [32] Treatment costs, cost offset, and cost-effectiveness of collaborative management of depression
    Von Korff, M
    Katon, W
    Bush, T
    Lin, EHB
    Simon, GE
    Saunders, K
    Ludman, E
    Walker, E
    Unutzer, J
    [J]. PSYCHOSOMATIC MEDICINE, 1998, 60 (02): : 143 - 149
  • [33] Cost-effectiveness and cost-utility study of a psychoeducational group intervention for people with depression and physical comorbidity in primary care
    Raya-Tena, Antonia
    Fernandez-San-Martin, Maria Isabel
    Martin-Royo, Jaume
    Casajuana-Closas, Marc
    Jimenez-Herrera, Maria Francisca
    [J]. ENFERMERIA CLINICA, 2024, 34 (02): : 108 - 119
  • [34] Cost-effectiveness, cost-utility and the budget impact of antidepressants versus preventive cognitive therapy with or without tapering of antidepressants
    Klein, Nicola S.
    Wijnen, Ben F. M.
    Lokkerbol, Joran
    Buskens, Erik
    Elgersma, Hermien J.
    van Rijsbergen, Gerard D.
    Slofstra, Christien
    Ormel, Johan
    Dekker, Jack
    de Jong, Peter J.
    Nolen, Willem A.
    Schene, Aart H.
    Hollon, Steven D.
    Burger, Huibert
    Bockting, Claudi L. H.
    [J]. BJPSYCH OPEN, 2019, 5 (01):
  • [35] Cost-effectiveness and cost-utility analysis of a work-place smoking cessation intervention with and without financial incentives
    van denBrand, Floor A.
    Nagelhout, Gera E.
    Winkens, Bjorn
    Chavannes, Niels H.
    vanSchayck, Onno C. P.
    Evers, Silvia M. A. A.
    [J]. ADDICTION, 2020, 115 (03) : 534 - 545
  • [36] Economic evaluation of dose-response resistance training in older women: a cost-effectiveness and cost-utility analysis
    Davis, J. C.
    Marra, C. A.
    Robertson, M. C.
    Khan, K. M.
    Najafzadeh, M.
    Ashe, M. C.
    Liu-Ambrose, T.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2011, 22 (05) : 1355 - 1366
  • [37] A cost-effectiveness analysis of bisoprolol for heart failure
    Varney, S
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2001, 3 (03) : 365 - 371
  • [38] Cost-effectiveness of the treatment of heart failure with ramipril: a Spanish analysis of the AIRE study
    Hart, WM
    Rubio-Terres, C
    Pajuelo, F
    Juanatey, JRG
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2002, 4 (04) : 553 - 558
  • [39] The cost-effectiveness of screening and treatment for hepatitis C in prisons in England and Wales: a cost-utility analysis
    Sutton, A. J.
    Edmunds, W. J.
    Sweeting, M. J.
    Gill, O. N.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2008, 15 (11) : 797 - 808
  • [40] Cost-effectiveness and cost-utility analysis of Haemate-P versus other von Willebrand disease treatments in Spain
    Megias-Vericat, Juan E.
    Escolar, Gines
    Wilson, Michele R.
    Mendez, Pablo
    Mcdade, Cheryl L.
    Barrientos, Laura Vidal
    Tomic, Radovan
    Panebianco, Marco
    Linden, Stephan
    Yan, Songkai
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2025, 28 (01) : 436 - 445
12345